Skip to main content

Table 2 Demographic and clinical features of the patient population

From: Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year

Feature n (224)
DIAGNOSIS
Juvenile idiopathic arthritis 100
 RF-negative polyarticular 35
 Enthesitis-related arthritis 24
 Oligoarticular 17
 Psoriatic 12
 Systemic 7
 RF+ polyarticular 5
Systemic lupus erythematosus 40
Inflammatory bowel disease-associated arthritis 18
Juvenile dermatomyositis 12
Idiopathic uveitis 10
Sjogren syndrome 8
Mixed connective tissue disease 7
Henoch-Schonlein purpura 5
Sarcoidosis 4
Chronic recurrent multifocal osteomyelitis 3
Other1 14
DEMOGRAPHICS
Female sex 161 (72%)
Age at initiation of infusion (years: mean ± SD) 11.5 ± 4.2
Age in 20152 (years: mean ± SD) 13.3 ± 4.0
THERAPY
Therapy duration (start – September 30, 2017); years: mean ± SD 2.8 ± 2.4
Use of antimetabolites3 183 (82%)
Outcome of infusions used in 2015
 Continued into 2016 1394
 Patient transferred care 19
 Changed to home/local infusions or subcutaneous administration 11
 Stopped due to disease control 33
 Stopped due to inefficacy 214
 Stopped due to adverse events 6
 Stopped as per parental choice 5
  1. 1The following diagnoses had 1 patient each: Behcet Syndrome, CREST (Calcinosis, Raynaud, Esophageal dysmotility, Sclerodactyly, Telangiectasia) syndrome, cutis laxa with restrictive lung disease, eosinophilic granulomatosis with polyangiitis, hyper IgD syndrome, idiopathic pulmonary hemosiderosis, immune-mediated glomerulonephritis, idiopathic thrombocytopenic purpura, mucolipidosis type IV, orbital pseudotumor, pemphigoid, primary angiitis of the central nervous system, polymyositis, relapsing polychondritis. 2Calculated as age mid-year (June 30, 2015). 3azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil. 4Ten patients were counted in both rows, due to switching from one infusion to another in 2015